The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Invasive aspergillosis is a leading cause of morbidity and mortality in immunocompromised patients. Therapeutic drug monitoring (TDM) is a strategy to optimise the outcome for a wide range of drug-disease combinations. Accumulating evidence suggests that TDM of the triazoles is required to optimise outcome of patients with invasive aspergillosis. TMD is also required for treatment with 5-flucytosine...
Micafungin is an echinocandin with broad spectrum activity against Candida spp. and Aspergillus spp. This agent is extensively used to treat these opportunistic fungal pathogens in immunocompromised hosts. This review summarises the clinical pharmacology of micafungin, including pharmacokinetics, pharmacodynamics and use in special populations.
Clin Microbiol Infect 2010; 16: 683–688
AbstractOral azole antifungal therapy is used extensively for all forms of aspergillosis, including allergic bronchopulmonary aspergillosis (ABPA). However, long‐term therapy may increase the risk of resistance. Here we report itraconazole and voriconazole resistance with reduced susceptibility to posaconazole in Aspergillus fumigatus in two patients exposed...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.